文献速递胸部肿瘤放疗

早期非小细胞肺癌接受笔束扫描粒子治疗:安全性与疗效早期结果的回顾性分析

Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy.
PubMed 文献 · Radiat Oncol · 2019-01-25

回顾性分析2014年8月至2018年3月连续31例N0-1、M0早期非小细胞肺癌患者接受笔束扫描质子或碳离子放疗的安全性与疗效。中位随访12.1个月,未观察到4-5级毒性,1年和2年无进展生存率、局部控制率、病因特异性生存率和总生存率分别为85.5%、95.2%、95.0%和90.7%。作者认为笔束扫描粒子治疗对早期非小细胞肺癌似乎安全有效,需进一步随访和研究。

要点

  • 31例早期NSCLC接受PBS质子或碳离子放疗,未观察到4-5级毒性,1例发生3级放射性肺损伤。
  • 1年和2年无进展生存率均为85.5%,局部控制率均为95.2%,总生存率均为90.7%。
  • 3例出现疾病进展,其中1例局部失败合并远处失败,1例区域及远处失败,1例仅远处失败。

核心结论

  • 基于笔束扫描的粒子治疗对早期非小细胞肺癌似乎安全有效。
  • 需要进一步随访和研究。

研究设计与样本

  • 回顾性分析2014年8月至2018年3月连续31例原发肿瘤与肺门淋巴结最长径之和<5 cm、N0-1、M0的NSCLC患者,均接受笔束扫描粒子治疗。
  • 20例和7例患者分别使用门控技术和主动呼吸控制技术控制肿瘤运动。
  • 通过Syngo®计划系统设计笔束扫描质子放疗或碳离子放疗计划;6例接受质子放疗,6例接受质子放疗+碳离子加强,19例接受碳离子放疗。
  • 处方剂量分为3个级别:5-7.5 GyE×8-10次、4-5 GyE×15-16次和2.25-3.5 GyE×20-31次。

主要发现

  • 31例患者中男20例、女11例,中位年龄71岁(范围50-80岁),中位随访时间12.1个月(范围2.9-45.2个月)。
  • 14例为腺癌,7例为鳞状细胞癌,4例为非特指NSCLC,6例无组织学诊断(其中4/6例有既往切除肺癌史)。
  • 中位肿瘤大小3.1 cm(范围1.1-4.7 cm)。
  • 未观察到4-5级毒性;1例在放疗开始后6.7个月发生3级放射性肺损伤(依据CTCAE v4.03)。
  • 2级急性毒性包括血液学毒性5例、放射性肺损伤2例、胸膜疼痛1例和皮炎1例;2级晚期毒性包括放射性肺损伤3例和无症状肋骨骨折1例。

关键数值与推荐

  • 纳入标准:原发肿瘤与肺门淋巴结最长径之和<5 cm、N0-1、M0的NSCLC。
  • 毒性分级依据Common Terminology Criteria for Adverse Events version 4.03。
  • 处方剂量3个级别:5-7.5 GyE×8-10次、4-5 GyE×15-16次、2.25-3.5 GyE×20-31次。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文为回顾性分析。
  • 中位随访时间12.1个月(范围2.9-45.2个月)。
  • 原文结论指出需要进一步随访和研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To evaluate the safety and efficacy of particle therapy (PT) using pencil beam scanning (PBS) technique for early stage non-small cell lung cancer (NSCLC). METHODS: From 08/2014 to 03/2018, 31 consecutive patients with sum of the longest diameters of primary tumor and hilar lymph node < 5 cm, N0-1, M0 NSCLC treated with PT were retrospectively analyzed. Gating/active breathing control techniques were used to control tumor motion in 20 and 7 patients. PBS-based proton radiotherapy (PRT) or carbon ion radiotherapy (CIRT) plans were designed via Syngo® planning system. PRT, PRT + CIRT boost, and CIRT were used in 6, 6 and 19 patients, respectively. Prescriptions were categorized to 3 levels: 5-7.5 GyE * 8-10 Fx, 4-5 GyE * 15-16 Fx and 2.25-3.5 GyE * 20-31 Fx. RESULTS: Thirty-one patients (20 males and 11 females) with a median age of 71 (50-80) years were enrolled with a median follow-up time of 12.1 (2.9-45.2) months. Fourteen were adenocarcinomas, 7 squamous cell carcinomas, 4 non-specified NSCLC and 6 had no histological diagnosis (4/6 had previous resected lung cancer). The median tumor size was 3.1 (1.1-4.7) cm. No grade 4-5 toxicities were observed. One patient experienced grade 3 (per the Common Terminology Criteria for Adverse Events version 4.03) radiation-induced lung injury (RILI) at 6.7 months from radiation started. Grade 2 acute toxicities included hematological toxicities (5 cases), RILI (2), plural pain (1) and dermatitis (1). Grade 2 late toxicities included RILI (3) and asymptomatic rib fracture (1). Three patients had progressed disease at 4.0~10.6 months after the initiation of PT. One experienced local failure with simultaneous distant failure and died of brain metastasis at 10.8 months; one developed regional and distant failure and died of lung infection at 8.7 months; the other experienced isolated distant failure only and his disease was well controlled after salvage systemic therapy. The estimated rates of progression-free survival, local control, cause-specific survival and overall survival at 1, 2 years were 85.5% and 85.5%, 95.2% and 95.2%, 95.0% and 95.0%, 90.7% and 90.7%, respectively. CONCLUSIONS: PBS-based PT appears safe and effective for early stage NSCLC. Further follow-up and investigation is warranted. TRIAL REGISTRATION: ISRCTN, ISRCTN78973763. Registered 14 August 2018- Retrospectively registered, http://www.isrctn.com/ISRCTN78973763 .

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen J, Lu JJ, Ma N, et al. Early stage non-small cell lung cancer treated with pencil beam scanning particle therapy: retrospective analysis of early results on safety and efficacy. Radiat Oncol. 2019. PMID: 30683133. doi:10.1186/s13014-019-1216-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。